SERA vs. CSTL, AUNA, TALK, FLGT, INNV, DCGO, EHAB, CELC, PSNL, and VMD
Should you be buying Sera Prognostics stock or one of its competitors? The main competitors of Sera Prognostics include Castle Biosciences (CSTL), Auna (AUNA), Talkspace (TALK), Fulgent Genetics (FLGT), InnovAge (INNV), DocGo (DCGO), Enhabit (EHAB), Celcuity (CELC), Personalis (PSNL), and Viemed Healthcare (VMD). These companies are all part of the "healthcare" industry.
Sera Prognostics vs.
Castle Biosciences (NASDAQ:CSTL) and Sera Prognostics (NASDAQ:SERA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations, community ranking and profitability.
Castle Biosciences has a net margin of 1.95% compared to Sera Prognostics' net margin of 0.00%. Castle Biosciences' return on equity of 1.47% beat Sera Prognostics' return on equity.
In the previous week, Castle Biosciences and Castle Biosciences both had 4 articles in the media. Castle Biosciences' average media sentiment score of 0.86 beat Sera Prognostics' score of 0.72 indicating that Castle Biosciences is being referred to more favorably in the media.
92.6% of Castle Biosciences shares are held by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are held by institutional investors. 7.2% of Castle Biosciences shares are held by insiders. Comparatively, 15.8% of Sera Prognostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Castle Biosciences currently has a consensus target price of $40.29, indicating a potential upside of 42.50%. Given Castle Biosciences' higher possible upside, analysts plainly believe Castle Biosciences is more favorable than Sera Prognostics.
Castle Biosciences received 81 more outperform votes than Sera Prognostics when rated by MarketBeat users. Likewise, 65.00% of users gave Castle Biosciences an outperform vote while only 38.46% of users gave Sera Prognostics an outperform vote.
Castle Biosciences has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, Sera Prognostics has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.
Sera Prognostics has lower revenue, but higher earnings than Castle Biosciences. Sera Prognostics is trading at a lower price-to-earnings ratio than Castle Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Castle Biosciences beats Sera Prognostics on 13 of the 16 factors compared between the two stocks.
Get Sera Prognostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SERA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sera Prognostics Competitors List
Related Companies and Tools
This page (NASDAQ:SERA) was last updated on 2/1/2025 by MarketBeat.com Staff
